At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 69 enrolled
Drug / intervention
Neostigmine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures
In Brief
A Phase 4 clinical trial evaluating Neostigmine, Glycopyrrolate, and 1 other intervention for Neuromuscular Blockade and Anesthesia. Completed, enrolled 69 participants across 1 site.
Detailed Summary
The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other half will receive Sugammadex.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade, Anesthesia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionDec 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedOct 26, 2017
Enrollment StartNov 14, 2017
Primary CompletionDec 31, 2020
Study CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 8.7 years ago
Interventions
Neostigminedrug
Neostigmine injection
Glycopyrrolatedrug
Glycopyrrolate injection
Sugammadexdrug
Sugammadex injection